Powder: -20°C for 3 years | In solvent: -80°C for 1 year
Apricitabine (SPD754) 是一种具有高选择性和口服活性的HIV-1逆转录酶抑制剂(Ki=0.08μM),是2′-脱氧-3′-氧-4′-硫代胞苷(dOTC)的(-)对映体 。 Apricitabine 对DNA 聚合酶α、β和γ具有抑制作用,Ki 值分别为300μM、12μM 和112.25μM。Apricitabine 在抗逆转录病毒HIV 感染者中显示出良好的抗逆转录病毒治疗效果,具有良好的耐受性和较低的选择性抗性。
规格 | 价格/CNY | 货期 | 数量 | |
---|---|---|---|---|
1 mg | ¥ 292 | 现货 | ||
5 mg | ¥ 651 | 现货 | ||
10 mg | ¥ 938 | 现货 | ||
25 mg | ¥ 1,575 | 现货 | ||
50 mg | ¥ 2,478 | 现货 | ||
100 mg | ¥ 3,980 | 现货 | ||
1 mL * 10 mM (in DMSO) | ¥ 515 | 现货 |
产品描述 | Apricitabine (SPD754) is a highly selective and orally active HIV-1 reverse transcriptase inhibitor (Ki=0.08 μM), the (-) enantiomer of 2′-deoxy-3′-oxy-4′-thiocytidine (dOTC) . Apricitabine inhibits DNA polymerase α, β and γ with Ki values of 300 μM, 12 μM and 112.25 μM, respectively. Apricitabine has shown good antiretroviral therapeutic efficacy in antiretroviral HIV-infected patients, with good tolerability and low selective resistance. |
靶点活性 | Abacavir resistant:32 μM, Wild-type (control):25 μM, Zidovudine-resistant:30 μM, Lamivudine-resistant:21 μM, HIV-1 (IIIB):20 μM, Zidovudine-resistant/lamivudine-resistant:55 μM |
体外活性 |
Apricitabine (SPD754 ; AVX754) is against clinical isolates of HIV-1 in cultured PBMCs with IC50 values of 0.2 μM, 1.45 μM, 2.2 μM and 2.4 μM for HIV-1RF, Wild type, 3TC resistant, 3TC and AZT resistant, respectively[1]. Apricitabine (SPD754 ; AVX754) has antiviral activities against HIV-1 clinical isolates resistant to nucleoside reverse transcriptase inhibitors in MT-4 cells, exhibits Mean IC50 values of 20 μM, 25 μM, 30 μM,21 μM,55 μM,32 μM and 71 μM. It is for HIV-1IIIB, Wild-type(control), Zidovudine-resistant/lamivudine-resistant, Zidovudine-resistant, Lamivudine-resistant, Abacavir-resistant and Stavudine-resistant viruses, respectively.[2] |
体内活性 | Apricitabine (SPD754 ; AVX754) (intravenous injection ; 10 mg/kg ; once a day) exhibits the T1/2, AUC0–∞ values of 12.7 mins, 226.9 μg/min/ml in female rats[1]. Apricitabine (SPD754 ; AVX754) (oral adminstation ; 10 mg/kg ; once a day) exhibits a good oral bioavailability of 68% for males and 69.4% for females rats and the T1/2, AUC0–∞, Tmax, Cmax are 62.2 mins, 157.4 μg/min/ml and 37.3 mins, 1.16 μg/ml in female rats.[1] |
别名 | AVX754, SPD754 |
分子量 | 229.26 |
分子式 | C8H11N3O3S |
CAS No. | 160707-69-7 |
Powder: -20°C for 3 years | In solvent: -80°C for 1 year
DMSO: 11 mg/mL (47.98 mM)
可选溶剂 | 浓度 体积 质量 | 1 mg | 5 mg | 10 mg | 25 mg |
DMSO | 1 mM | 4.3619 mL | 21.8093 mL | 43.6186 mL | 109.0465 mL |
5 mM | 0.8724 mL | 4.3619 mL | 8.7237 mL | 21.8093 mL | |
10 mM | 0.4362 mL | 2.1809 mL | 4.3619 mL | 10.9046 mL | |
20 mM | 0.2181 mL | 1.0905 mL | 2.1809 mL | 5.4523 mL |
对于不同动物的给药剂量换算,您也可以参考 更多...
请在以下方框中输入您的动物实验信息后点击计算,可以得到母液配置方法和体内配方的制备方法: 比如您的给药剂量是10 mg/kg,每只动物体重20 g,给药体积100 μL,一共给药动物10 只,您使用的配方为5% DMSO+30% PEG300+5% Tween 80+60% ddH2O。那么您的工作液浓度为2 mg/mL。
母液配置方法:2 mg 药物溶于 50 μL DMSO (母液浓度为 40 mg/mL), 如您需要配置的浓度超过该产品的溶解度,请先与我们联系。
体内配方的制备方法:取 50 μL DMSO 主液,加入 300 μL PEG300, 混匀澄清,再加 50 μL Tween 80,混匀澄清,再加 600 μL ddH2O, 混匀澄清。
您可能有的问题的答案可以在抑制剂处理说明中找到,包括如何准备库存溶液,如何存储产品,以及基于细胞的分析和动物实验需要特别注意的问题。
Apricitabine 160707-69-7 Cell Cycle/Checkpoint DNA Damage/DNA Repair Microbiology/Virology Proteases/Proteasome HIV Protease DNA/RNA Synthesis SPD-754 AVX754 SPD 754 SPD754 AVX 754 AVX-754 Inhibitor inhibitor inhibit